Shares of Sarepta Therapeutics Inc. (SRPT) are already down over 57% in just three trading days as the company anxiously awaits FDA panel vote on Eteplirsen, its drug candidate for Duchenne Muscular Dystrophy amenable to exon 51 skipping.
Forex – financial instrument.Forex news
Shares of Sarepta Therapeutics Inc. (SRPT) are already down over 57% in just three trading days as the company anxiously awaits FDA panel vote on Eteplirsen, its drug candidate for Duchenne Muscular Dystrophy amenable to exon 51 skipping.